vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and TOOTSIE ROLL INDUSTRIES INC (TR). Click either name above to swap in a different company.
TOOTSIE ROLL INDUSTRIES INC is the larger business by last-quarter revenue ($196.3M vs $139.2M, roughly 1.4× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 14.7%, a 20.8% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 1.5%). TOOTSIE ROLL INDUSTRIES INC produced more free cash flow last quarter ($61.0M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 13.2%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Tootsie Roll Industries is an American manufacturer of confectionery based in Chicago, Illinois. Its best-known products include the namesake Tootsie Rolls and Tootsie Pops. Tootsie Roll Industries currently markets its brands internationally in Canada, Mexico, and over 75 other countries.
ADMA vs TR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $196.3M |
| Net Profit | $49.4M | $28.8M |
| Gross Margin | 63.8% | 35.7% |
| Operating Margin | 45.1% | 17.0% |
| Net Margin | 35.5% | 14.7% |
| Revenue YoY | 18.4% | 1.5% |
| Net Profit YoY | -55.9% | 27.9% |
| EPS (diluted) | $0.20 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $196.3M | ||
| Q3 25 | $134.2M | $232.7M | ||
| Q2 25 | $122.0M | $155.1M | ||
| Q1 25 | $114.8M | $148.5M | ||
| Q4 24 | $117.5M | $193.4M | ||
| Q3 24 | $119.8M | $225.9M | ||
| Q2 24 | $107.2M | $150.7M | ||
| Q1 24 | $81.9M | $153.2M |
| Q4 25 | $49.4M | $28.8M | ||
| Q3 25 | $36.4M | $35.7M | ||
| Q2 25 | $34.2M | $17.5M | ||
| Q1 25 | $26.9M | $18.1M | ||
| Q4 24 | $111.9M | $22.5M | ||
| Q3 24 | $35.9M | $32.8M | ||
| Q2 24 | $32.1M | $15.6M | ||
| Q1 24 | $17.8M | $15.8M |
| Q4 25 | 63.8% | 35.7% | ||
| Q3 25 | 56.3% | 34.1% | ||
| Q2 25 | 55.1% | 36.4% | ||
| Q1 25 | 53.2% | 35.3% | ||
| Q4 24 | 53.9% | 39.1% | ||
| Q3 24 | 49.8% | 34.1% | ||
| Q2 24 | 53.6% | 33.5% | ||
| Q1 24 | 47.8% | 32.7% |
| Q4 25 | 45.1% | 17.0% | ||
| Q3 25 | 38.0% | 13.9% | ||
| Q2 25 | 35.1% | 7.8% | ||
| Q1 25 | 30.4% | 15.5% | ||
| Q4 24 | 32.6% | 20.0% | ||
| Q3 24 | 33.1% | 15.6% | ||
| Q2 24 | 36.6% | 10.2% | ||
| Q1 24 | 26.7% | 7.3% |
| Q4 25 | 35.5% | 14.7% | ||
| Q3 25 | 27.1% | 15.3% | ||
| Q2 25 | 28.1% | 11.3% | ||
| Q1 25 | 23.4% | 12.2% | ||
| Q4 24 | 95.2% | 11.6% | ||
| Q3 24 | 30.0% | 14.5% | ||
| Q2 24 | 29.9% | 10.4% | ||
| Q1 24 | 21.7% | 10.3% |
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.15 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.15 | — | ||
| Q2 24 | $0.13 | — | ||
| Q1 24 | $0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $176.6M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $941.0M |
| Total Assets | $624.2M | $1.3B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $176.6M | ||
| Q3 25 | $61.4M | $119.8M | ||
| Q2 25 | $90.3M | $170.5M | ||
| Q1 25 | $71.6M | $176.6M | ||
| Q4 24 | $103.1M | $194.6M | ||
| Q3 24 | $86.7M | $163.2M | ||
| Q2 24 | $88.2M | $131.2M | ||
| Q1 24 | $45.3M | $159.4M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $941.0M | ||
| Q3 25 | $431.2M | $918.9M | ||
| Q2 25 | $398.3M | $893.1M | ||
| Q1 25 | $373.4M | $879.4M | ||
| Q4 24 | $349.0M | $870.7M | ||
| Q3 24 | $231.9M | $870.2M | ||
| Q2 24 | $188.3M | $841.4M | ||
| Q1 24 | $153.7M | $834.4M |
| Q4 25 | $624.2M | $1.3B | ||
| Q3 25 | $568.7M | $1.2B | ||
| Q2 25 | $558.4M | $1.2B | ||
| Q1 25 | $510.6M | $1.1B | ||
| Q4 24 | $488.7M | $1.1B | ||
| Q3 24 | $390.6M | $1.1B | ||
| Q2 24 | $376.4M | $1.1B | ||
| Q1 24 | $350.9M | $1.1B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $73.3M |
| Free Cash FlowOCF − Capex | $34.6M | $61.0M |
| FCF MarginFCF / Revenue | 24.8% | 31.1% |
| Capex IntensityCapex / Revenue | 0.8% | 6.3% |
| Cash ConversionOCF / Net Profit | 0.72× | 2.55× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $96.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $73.3M | ||
| Q3 25 | $13.3M | $62.2M | ||
| Q2 25 | $21.1M | $-8.5M | ||
| Q1 25 | $-19.7M | $3.6M | ||
| Q4 24 | $50.2M | $68.8M | ||
| Q3 24 | $25.0M | $61.3M | ||
| Q2 24 | $45.6M | $-12.6M | ||
| Q1 24 | $-2.2M | $21.4M |
| Q4 25 | $34.6M | $61.0M | ||
| Q3 25 | $-1.1M | $50.7M | ||
| Q2 25 | $18.7M | $-16.0M | ||
| Q1 25 | $-24.4M | $750.0K | ||
| Q4 24 | $47.5M | $64.7M | ||
| Q3 24 | $24.0M | $55.8M | ||
| Q2 24 | $43.6M | $-16.6M | ||
| Q1 24 | $-4.6M | $16.9M |
| Q4 25 | 24.8% | 31.1% | ||
| Q3 25 | -0.8% | 21.8% | ||
| Q2 25 | 15.3% | -10.3% | ||
| Q1 25 | -21.2% | 0.5% | ||
| Q4 24 | 40.4% | 33.5% | ||
| Q3 24 | 20.0% | 24.7% | ||
| Q2 24 | 40.7% | -11.0% | ||
| Q1 24 | -5.6% | 11.0% |
| Q4 25 | 0.8% | 6.3% | ||
| Q3 25 | 10.7% | 5.0% | ||
| Q2 25 | 2.0% | 4.8% | ||
| Q1 25 | 4.1% | 1.9% | ||
| Q4 24 | 2.3% | 2.1% | ||
| Q3 24 | 0.9% | 2.4% | ||
| Q2 24 | 1.9% | 2.6% | ||
| Q1 24 | 2.9% | 2.9% |
| Q4 25 | 0.72× | 2.55× | ||
| Q3 25 | 0.36× | 1.74× | ||
| Q2 25 | 0.62× | -0.49× | ||
| Q1 25 | -0.73× | 0.20× | ||
| Q4 24 | 0.45× | 3.06× | ||
| Q3 24 | 0.70× | 1.87× | ||
| Q2 24 | 1.42× | -0.81× | ||
| Q1 24 | -0.12× | 1.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
TR
| Products | $194.3M | 99% |
| Rental And Royalty | $1.9M | 1% |
